Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its partner Eisai Co Ltd (TYO:4523) announced on Wednesday that the European Commission has granted marketing authorisation for Leqembi (lecanemab), marking the first EU-approved therapy targeting an underlying cause of Alzheimer's disease.
This approval entitles BioArctic to a milestone payment of EUR20m from Eisai.
Leqembi is indicated for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, specifically ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. It is a monoclonal antibody designed to clear toxic Aβ protofibrils and reduce Aβ plaques in the brain.
The treatment addresses a significant unmet need, with early Alzheimer's disease affecting over 22 million people across Europe. Leqembi is expected to help slow disease progression and reduce societal burden.
Originally developed by BioArctic based on research by Professor Lars Lannfelt, Leqembi is now being commercialised globally by Eisai. In the Nordic region, BioArctic and Eisai will co-commercialise the therapy.
The centralised EU authorisation covers all member states, as well as Norway, Iceland and Liechtenstein. Leqembi is also approved in the United States, Japan, China, Great Britain and other markets.
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
MHRA to review monthly maintenance dosing for Leqembi in early Alzheimer's treatment
Ro integrates with NovoCare Pharmacy to offer access to all doses of Wegovy at lowest price
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy